Therefore, when two or more gene mutations of KEAP1, STK11, PBRM1 and SMARCA4 coexist in NSCLC patients, especially in LUAD patients, it is still necessary to use immunotherapy with caution. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.